Benefits
Triglyceride reduction
The most consistent fish oil benefit. Prescription-strength EPA+DHA or EPA-only at 4 g/day, a dose used under medical supervision, reduces triglycerides by 30% or more, as monotherapy or alongside statins. Lower OTC doses (1 to 2 g/day) produce more modest 11 to 15% reductions. Caveat: EPA+DHA may slightly raise LDL when treating severe hypertriglyceridemia (≥500 mg/dL), while purified EPA-only does not.
Cardiovascular events: formulation matters
In one large trial of statin-treated high-risk patients, icosapent ethyl 4 g/day was associated with 25% fewer major cardiovascular events. Note carefully what that product is: icosapent ethyl (Vascepa) is a prescription drug (purified EPA ethyl ester taken at 4 g/day under medical supervision), not an over-the-counter fish oil supplement, and the result should not be read across to retail capsules. EPA+DHA combinations have not replicated this in similar populations. Whether the difference is genuinely about EPA vs. combination, or about contested placebo choices, is not fully resolved. The cardiovascular case for routine over-the-counter fish oil is much weaker, and the trial record says so directly: VITAL (1 g/day, general adults) missed its primary endpoint, ASCEND (1 g/day, adults with diabetes) found no difference in serious vascular events, and STRENGTH (EPA+DHA 4 g/day) was stopped for futility. The large well-powered supplement trials are null.
Atrial fibrillation risk at high doses
At high doses, mostly prescription omega-3 drugs at 1.8 to 4 g/day given to people with heart disease or high cardiovascular risk, trials found more atrial fibrillation with both EPA-only and EPA+DHA products. The absolute increase was about 1 percentage point over several years (in REDUCE-IT, hospitalization for atrial fibrillation or flutter was 3.1% vs. 2.1%), but larger in people who already had atrial fibrillation (12.5% vs. 6.3%). At about 1 g/day, the largest trial, VITAL Rhythm, found no significant difference from placebo, although pooled analyses cannot rule out a small increase. Anyone with atrial fibrillation or other heart rhythm problems should talk to a cardiologist before starting high-dose omega-3.
Mood support, studied as an add-on in major depression
Pooled analyses of trials in people diagnosed with major depression report modest reductions in depressive symptom scores when EPA-rich omega-3 is added to standard antidepressant therapy, and the effect has been reasonably reproducible across trials. Depression is a medical condition that requires professional diagnosis and care; omega-3 is not a substitute for treatment, and adding it alongside prescribed therapy should be discussed with the treating clinician. Critically, formulation matters: EPA needs to be at least 60% of total omega-3 content for reliable benefit. Most retail 'fish oil' products aren't EPA-dominant enough, so read the label. Best used as adjunct at 1-2 g EPA/day, not as monotherapy for clinical depression.
Pregnancy and infant brain development
DHA is the dominant fatty acid in fetal and infant brain tissue. Maternal DHA status during pregnancy and breastfeeding correlates with infant visual and cognitive outcomes. WHO and most national obstetric bodies recommend 200-300 mg DHA per day during pregnancy and lactation. Choose third-party-tested anchovy/sardine or algal oil to minimize mercury exposure. Avoid cod liver oil during pregnancy: its vitamin A content carries teratogenicity risk.
Joint comfort, studied as an add-on in rheumatoid arthritis
At higher doses (2-4 g/day combined EPA+DHA), trials in people already diagnosed with rheumatoid arthritis have reported small-to-moderate reductions in tender and swollen joint counts and in morning stiffness, and some report reduced NSAID use. Rheumatoid arthritis is a diagnosed disease requiring medical management; these are reported outcomes in patients under care, not a claim that fish oil treats arthritis. Consistent across meta-analyses but the clinical magnitude is modest: a useful adjunct, not disease-modifying. Reasonable component of comprehensive RA management under rheumatologist supervision.
Quality and oxidation matter: much cheap fish oil is oxidized
Fish oil oxidizes readily, and rancid oil may be pro-inflammatory rather than anti-inflammatory. Independent testing (IFOS, USP, ConsumerLab) consistently finds wide variation in actual EPA/DHA content and oxidation levels across retail products. Practical guidance: choose products with antioxidants added, opaque packaging, and recent manufacturing dates. Refrigerate after opening. Discard any oil with strong fishy or rancid smell; that's the opposite of what you want.
Mechanism of action
Hepatic VLDL synthesis reduction (triglyceride mechanism)
Pharmaceutical doses (≥3 g/day) reduce hepatic synthesis and secretion of very-low-density lipoprotein (VLDL) by approximately 30%. Kinetic studies confirm that reduced VLDL output, not increased clearance, accounts for most of the triglyceride lowering. This is dose-dependent, which explains why low supplement doses don't significantly affect triglycerides while pharmaceutical doses do.
Eicosanoid pathway modulation
EPA and DHA partially displace arachidonic acid from cell membrane phospholipids. When inflammation occurs, this membrane composition shift produces less inflammatory series-2 prostaglandins/thromboxanes and series-4 leukotrienes, and more anti-inflammatory series-3 prostaglandins, series-5 leukotrienes, and specialized pro-resolving mediators (resolvins, protectins, maresins). The mechanism takes weeks to develop because membrane turnover is slow.
Membrane composition and cell function
DHA is preferentially incorporated into neuronal and retinal membrane phospholipids, where it influences membrane fluidity, receptor function, and synaptic activity. This is the basis for the developmental DHA recommendation in pregnancy and infancy. It has also been proposed to matter for cognition in aging, but randomized trials in cognitively healthy older adults have not shown a benefit on cognitive decline. EPA is more evenly distributed across triglycerides, cholesterol esters, and phospholipids.
Why EPA and DHA are not interchangeable
Clinical effects differ. EPA-dominant preparations have the stronger trial record for mood outcomes, and the only large positive cardiovascular trial used a prescription purified-EPA drug (icosapent ethyl) rather than a fish oil supplement. DHA is more important for fetal/infant neural development and may be more relevant to cognitive applications in adults. In humans, dietary DHA can be retroconverted to EPA, but EPA→DHA conversion is minimal; these are functionally distinct fatty acids despite both being marine omega-3s.
Resolution of inflammation (specialized pro-resolving mediators)
EPA and DHA are precursors to resolvins (E-series from EPA, D-series from DHA), protectins, and maresins: specialized pro-resolving mediators that actively turn off inflammation rather than simply suppress it. This is a different concept from anti-inflammatory drugs (which block inflammation initiation) and is the focus of much recent research.
Clinical trials
8,179 statin-treated patients with established CVD or diabetes plus risk factors, elevated triglycerides (135-499 mg/dL), randomized to icosapent ethyl 4 g/day or mineral oil placebo over median 4.9 years.
Clinical population described in trial publication.
8,179 statin-treated patients with established CVD or diabetes plus risk factors, elevated triglycerides (135-499 mg/dL), randomized to icosapent ethyl 4 g/day or mineral oil placebo over median 4.9 years. Primary composite endpoint (CV death, MI, stroke, revascularization, unstable angina) occurred in 17.2% on EPA vs. 22.0% placebo (HR 0.75, a 25% relative risk reduction). Cardiovascular death reduced 20%. Hospitalization for atrial fibrillation or flutter was higher on the drug (3.1% vs. 2.1%, P=0.004), while fatal or nonfatal stroke was lower (2.4% vs. 3.3%). Led to FDA approval of Vascepa for cardiovascular risk reduction in 2019. Essential context: the agent tested was icosapent ethyl, a prescription drug consisting of purified EPA ethyl ester, given at 4 g/day under medical supervision to a high-risk statin-treated population. It is not an over-the-counter fish oil supplement, and these outcomes do not transfer to retail EPA+DHA products.
13,078 statin-treated patients with high CV risk and atherogenic dyslipidemia randomized to omega-3 carboxylic acid (EPA+DHA) 4 g/day or corn oil placebo.
Clinical population described in trial publication.
13,078 statin-treated patients with high CV risk and atherogenic dyslipidemia randomized to omega-3 carboxylic acid (EPA+DHA) 4 g/day or corn oil placebo. Trial stopped early for futility, with no significant difference in the primary cardiovascular endpoint (12.0% vs. 12.2%). New-onset atrial fibrillation reported by investigators was higher on omega-3 (2.2% vs. 1.3%, HR 1.69). The STRENGTH authors raised the possibility that REDUCE-IT's benefit partly reflected more events on its mineral oil placebo; the debate is unresolved.
Comprehensive review concluded prescription EPA+DHA or EPA-only at 4 g/day (>3 g/day total EPA+DHA) is effective and safe for reducing triglycerides as monotherapy or with other lipid agents.
Clinical population described in trial publication.
Comprehensive review concluded prescription EPA+DHA or EPA-only at 4 g/day (>3 g/day total EPA+DHA) is effective and safe for reducing triglycerides as monotherapy or with other lipid agents. Triglyceride reduction ≥30% at this dose; smaller effects at lower doses. EPA-only formulations don't raise LDL while EPA+DHA at high doses can cause modest LDL increase in very high triglyceride patients.
Meta-analysis of 26 double-blind randomized placebo-controlled trials with 2,160 participants. (Liao et al. 2019, Transl Psychiatry)
2,160 participants
This meta-analysis of 26 double-blind randomized placebo-controlled trials with 2,160 participants found a modest overall reduction in depressive symptoms (pooled SMD -0.28), with reliable benefit confined to EPA-predominant formulations (at least 60% EPA) at up to about 1 g EPA/day; DHA-predominant preparations showed no benefit. Best positioned as an adjunct for people already under professional care for major depression, not as a primary treatment. Major depressive disorder requires clinical diagnosis and management.